Accessibility Menu

Some price data may be temporarily unavailable.

KEY DATA POINTS

Current Price
$0.00
Daily Change
(-) $0.00
Day's Range
$0.00 - $0.00
Previous Close
$0.00
Open
$0.00
Beta
0
Volume
-
Average Volume
-
Market Cap
-
Market Cap / Employee
-
52wk Range
$0.00 - $0.00
Revenue
-
Gross Margin
-
Dividend Yield
-
EPS
$0.00
CAPs Rating
-
Industry
Biotechnology

The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More

Surface Oncology Company Info

Surface Oncology, Inc. operates as a clinical-stage immuno-oncology company, which engages in the provision of biological pathways critical to the immunosuppressive tumor microenvironment for the development of next-generation cancer therapies. The firm’s pipeline includes wholly-owned lead programs targeting CD39 (SRF617) and IL-27 (SRF388), as well as a preclinical program focused on depleting tumor regulatory T cells via targeting CCR8 (SRF114). Its pipeline also includes licensed product programs, such as a collaboration with Novartis targeting CD73 (NZV930, Phase 1) and a collaboration with GlaxoSmithKline targeting PVRIG (SRF813, preclinical). The company was founded by David S. Grayzel in 2014 and is headquartered in Cambridge, MA.

News & Analysis

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.